Two phrases circulate in GLP-1 conversations that sound like the same thing and are not. The first, delayed gastric emptying, is in the prescribing information for these medicines, stated plainly, as a mechanism. The second, gastroparesis, is the name of a medical condition that only a clinician can diagnose. Headlines tend to use them interchangeably, and the swap quietly converts a property of the medicine into a diagnosis of the person.
Untangling the two is worth doing precisely, because each phrase carries different practical consequences. One tells you what the medicine is doing on purpose. The other opens a diagnostic road that involves testing, clinical judgment and time. This article walks through what the labels say, what the evidence shows, and where the line between the two actually falls.
What the label actually says
The prescribing information for these medicines says, in plain terms, that they delay gastric emptying. The wording appears as description, not as warning, because the delay is part of the mechanism: slowing the stomach is one of the ways the medicine produces its effects on appetite and, after meals, on glucose. A mechanism the label describes on purpose is a different thing from a malfunction, and reading it otherwise is where the trouble starts.
The label does draw practical consequences from the delay, and they are worth knowing exactly. In the Drug Interactions sections, the labels note that the delay may affect the absorption of oral medicines taken at the same time, and they advise clinical monitoring. What that means for pills you take alongside a GLP-1 is covered in GLP-1s and Your Other Pills: What the Labels Say About Timing, which owns that subject.
The second consequence appears in the Wegovy and Zepbound labels as a warning about pulmonary aspiration during general anesthesia or deep sedation. The warning cites the delay in gastric emptying and rare postmarketing reports of aspiration in patients undergoing elective procedures. Why anesthesia teams care, and what they ask about it, is the subject of GLP-1s Before Surgery: Why the Anesthesia Team Asks; what matters here is that even the warning is framed around the mechanism, not around a diagnosis.
Mechanism versus diagnosis
So what separates the two phrases? Delayed gastric emptying is a physiological event: the stomach holds its contents longer than it otherwise would. Gastroparesis is a clinical diagnosis, and the diagnosis means several things at once: delayed emptying documented by testing, together with ongoing symptoms, together with the absence of any blockage that would explain them. It is a conclusion a clinician reaches with instruments, not a feeling a person has after a meal.
The distinction is practical rather than pedantic, and here is why. Digestive symptoms during GLP-1 treatment, especially during the titration climb, are common and typically settle as weeks pass at a given dose. A diagnosis of gastroparesis, by contrast, requires formal testing and persists as a condition with its own management. Someone who treats every episode of fullness as incipient gastroparesis is reading a dose-adjustment window as a chronic disease.
The everyday digestive territory, the burping and bloating and gas that come with a slower stomach, has a guide of its own, and it belongs to the symptom side of this line rather than the diagnosis side.
GLP 1 Tracker AppLog digestive symptoms with a severity next to your doses, so a clinician sees a pattern instead of a memory.
Get the app
Gastroparesis in the label, in its proper place
The word gastroparesis does appear in these labels, and it is worth seeing exactly where. It shows up as a pre-existing condition: within the warning about severe gastrointestinal adverse reactions, the labels state that the medicine is not recommended in patients with severe gastroparesis. That sentence is doing the work of screening, describing who these medicines are generally not for. It is not describing what the medicines do.
Read that way, the label's own treatment of the word is a model for this whole article. The medicine delays stomach emptying, a mechanism; some people arrive with severe gastroparesis already diagnosed, a condition; and the label keeps the two firmly apart. Headlines that merge them are less careful than the document they summarize.
What postmarketing reports can and cannot say
The labels also carry postmarketing sections, and those list ileus, intestinal obstruction, and severe constipation including fecal impaction. It is easy to read a list like that as an answer. It is better read as a set of reports with an explicit caveat attached.
The labels state the caveat themselves: the reports come voluntarily from a population of uncertain size, so the frequency of these events cannot be reliably estimated, and a causal relationship to the medicine cannot be established. That is not legal boilerplate; it is the epistemology of the section. Voluntary reporting tells you what has been noticed and sent in, never how often it happens, and never whether the medicine caused it. Anyone quoting the list without the caveat is quoting half of it.
This is the pattern to carry into any conversation about these medicines and serious digestive events: the labels document reports, the reports cannot establish causation, and the weighing of both belongs to clinicians and regulators rather than to a search session.
The 2023 claims analysis
One study drives most of the gastroparesis headlines, so it deserves a careful paragraph. In 2023, an analysis published in JAMA used a large insurance claims database to compare people taking GLP-1 medicines for weight loss with people taking a different weight-loss medicine. It reported more diagnoses of gastroparesis, bowel obstruction and pancreatitis in the GLP-1 group.
Two properties of that study set the limits of what it can tell you. It was retrospective, looking backward at records rather than assigning treatments, and it therefore could not establish cause. And the events in question were rare. Those two facts together are why the study reads as a signal worth further research rather than a verdict, and why this article reports it without the numbers the headlines attached to it.
When to call rather than wait
None of this careful framing means digestive symptoms should always be waited out. Some situations are calls, promptly, whatever the ultimate explanation turns out to be:
- Vomiting that will not stop, or being unable to keep fluids down
- Severe or persistent bloating
- Still feeling full many hours after eating, repeatedly
Those symptoms warrant contacting a clinician rather than adding another log entry and watching. The log serves the milder tier, and the next section is about that. Sorting severe from ordinary is a clinician's job, and the faster they have the record, the better that job goes.
Making the pattern visible
For everything short of the call-the-clinician tier, the tool that earns its place is a symptom log with a severity on each entry. Feeling overly full after meals in week one of a new dose step, easing to mild by week three, is a pattern a prescriber recognizes immediately. The same sensations remembered as a vague month of discomfort are much harder to act on.
The app's side effect diary is built for this: each entry takes a symptom, a severity and an optional note, and it sits on the same timeline as the dose log, so the relationship between dose steps and digestive trouble is visible rather than inferred. The general practice, including what clinicians ask for, is laid out in How to Track GLP-1 Side Effects (and What to Show Your Doctor).
That is the practical resolution of the distinction this article opened with. You cannot diagnose yourself, and you should not try. What you can do is keep a dated, severity-rated record that makes the diagnostic conversation shorter and better informed, and leave the diagnosis itself to the testing and judgment it requires.
Frequently asked questions
Do GLP-1 medications cause gastroparesis?
The labels do not say that, and no source can honestly say it as settled fact. The prescribing information states that these medicines delay gastric emptying, which is part of how they work, and a 2023 retrospective claims analysis reported more gastroparesis diagnoses among GLP-1 users, but it could not establish cause and the events were rare. Gastroparesis itself is a clinical diagnosis that requires testing. The honest answer holds all of that at once: mechanism yes, headlines simplified, causation unresolved.
What is the difference between delayed gastric emptying and gastroparesis?
Delayed gastric emptying is a mechanism: the prescribing information for GLP-1 medications states plainly that they slow how quickly the stomach empties, on purpose, as part of how they work. Gastroparesis is a diagnosis: delayed emptying documented by testing, together with ongoing symptoms and the absence of any blockage, established by a clinician. One describes what a medicine does; the other names a condition a person is determined to have. Confusing the two turns every full feeling into a diagnosis.
Why do the GLP-1 labels mention severe gastroparesis?
Because it appears as a pre-existing condition, not as an effect. Within the warning about severe gastrointestinal adverse reactions, the labels state that the medicine is not recommended in patients with severe gastroparesis. In other words, the label is describing who should generally not use these medicines, not what the medicines do. Whether that applies to anyone's individual situation is a question for their clinician, not something to conclude from a label.
What do the labels say about anesthesia and stomach emptying?
The Wegovy and Zepbound labels carry a warning about pulmonary aspiration during general anesthesia or deep sedation. The warning cites the delay in gastric emptying and rare postmarketing reports of aspiration in patients undergoing elective procedures. That is why anesthesia teams ask about these medicines before procedures. What to do about it before a scheduled procedure is decided between you and the clinical team; it is never a reason to pause anything on your own.
When are GLP-1 digestive symptoms urgent enough to call about?
Some situations should skip the log and go straight to a call: vomiting that will not stop, being unable to keep fluids down, severe or persistent bloating, and still feeling full many hours after eating. Those warrant contacting a clinician promptly rather than waiting to see whether the pattern settles. Ordinary discomfort that fades over hours or days is different, and a severity-rated symptom log serves that milder tier well. When in doubt, calling is the safer read of the situation.